Suppr超能文献

老年患者的他汀类药物治疗

Treatment with Statins in Elderly Patients.

作者信息

Horodinschi Ruxandra-Nicoleta, Stanescu Ana Maria Alexandra, Bratu Ovidiu Gabriel, Pantea Stoian Anca, Radavoi Daniel George, Diaconu Camelia Cristina

机构信息

University of Medicine and Pharmacy "Carol Davila", 020021 Bucharest, Romania.

Clinical Emergency Hospital of Bucharest, 14461 Bucharest, Romania.

出版信息

Medicina (Kaunas). 2019 Oct 30;55(11):721. doi: 10.3390/medicina55110721.

Abstract

Elderly patients are a special category of patients, due to the physiological changes induced by age, the great number of comorbidities and drug treatment and last, but not least, to the cognitive dysfunction frequently encountered in this population. Cardiovascular disease is the most important cause of morbidity and mortality in elderly individuals worldwide. The rate of cardiovascular events increases after 65 years in men and after 75 years in women. Myocardial infarction and stroke are the leading disorders caused by atherosclerosis, that lead to death or functional incapacity. Elderly people have a greater risk to develop atherosclerotic cardiovascular disease. The incidence and prevalence of atherosclerosis increase with age and the number of cardiovascular events is higher in elderly patients. The most efficient treatment against atherosclerosis is the treatment with statins, that has been shown to decrease the risk both of stroke and coronary artery disease in all age groups. The advantages of the treatment become evident after at least one year of treatment. Primary prevention is the most important way of preventing cardiovascular disease in elderly individuals, by promoting a healthy lifestyle and reducing the risk factors. Secondary prevention after a stroke or myocardial infarction includes mandatory a statin, to diminish the risk of a recurrent cardiovascular event. The possible side effects of statin therapy are diabetes mellitus, myopathy, and rhabdomyolysis, hepatotoxicity. The side effects of the treatment are more likely to occur in elderly patients, due to their multiple associated comorbidities and drugs that may interact with statins. In elderly people, the benefits and disadvantages of the treatment with statins should be put in balance, especially in those receiving high doses of statins.

摘要

老年患者是一类特殊的患者群体,这是由于年龄引起的生理变化、大量的合并症和药物治疗,以及最后但同样重要的是,该人群中经常出现的认知功能障碍。心血管疾病是全球老年个体发病和死亡的最重要原因。男性65岁后、女性75岁后心血管事件发生率增加。心肌梗死和中风是由动脉粥样硬化引起的主要疾病,可导致死亡或功能丧失。老年人患动脉粥样硬化性心血管疾病的风险更高。动脉粥样硬化的发病率和患病率随年龄增长而增加,老年患者的心血管事件数量更高。对抗动脉粥样硬化最有效的治疗方法是使用他汀类药物,已证明其可降低所有年龄组中风和冠状动脉疾病的风险。治疗的益处至少在治疗一年后才会显现出来。一级预防是预防老年个体心血管疾病的最重要方式,即通过促进健康的生活方式和降低风险因素来实现。中风或心肌梗死后的二级预防包括必须使用他汀类药物,以降低心血管事件复发的风险。他汀类药物治疗可能的副作用包括糖尿病、肌病、横纹肌溶解、肝毒性。由于老年患者存在多种合并症以及可能与他汀类药物相互作用的药物,治疗的副作用在老年患者中更易发生。在老年人中,应权衡他汀类药物治疗的利弊,尤其是在接受高剂量他汀类药物治疗的患者中。

相似文献

1
Treatment with Statins in Elderly Patients.
Medicina (Kaunas). 2019 Oct 30;55(11):721. doi: 10.3390/medicina55110721.
2
A systematic review and economic evaluation of statins for the prevention of coronary events.
Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. doi: 10.3310/hta11140.
3
Dyslipidemia and Cardiovascular Prevention in the Elderly: A Balance between Benefits and Risks of Statin Treatment in a Specific Population.
Endocr Metab Immune Disord Drug Targets. 2023;23(11):1371-1379. doi: 10.2174/1871530323666230428092828.
4
Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis.
J Am Coll Cardiol. 2013 Dec 3;62(22):2090-9. doi: 10.1016/j.jacc.2013.07.069. Epub 2013 Aug 28.
5
Statin Prescribing in the Elderly: Special Considerations.
Curr Atheroscler Rep. 2017 Oct 11;19(11):47. doi: 10.1007/s11883-017-0683-9.
6
Statins in the elderly: a patient-focused approach.
Clin Cardiol. 2015 Jan;38(1):56-61. doi: 10.1002/clc.22338. Epub 2014 Oct 21.
8
Low use of statins for secondary prevention in primary care: a survey in a northern Swedish population.
BMC Fam Pract. 2016 Aug 11;17(1):110. doi: 10.1186/s12875-016-0505-0.
9
Statins, risk of diabetes, and implications on outcomes in the general population.
J Am Coll Cardiol. 2012 Oct 2;60(14):1231-8. doi: 10.1016/j.jacc.2012.05.019. Epub 2012 Aug 8.

引用本文的文献

2
The role of gut microbiota on skeletal muscle strength in LDLR knockdown aging mice.
Sci Rep. 2025 May 2;15(1):15319. doi: 10.1038/s41598-025-00059-6.
4
Influence of Ageing on the Pharmacodynamics and Pharmacokinetics of Chronically Administered Medicines in Geriatric Patients: A Review.
Clin Pharmacokinet. 2025 Mar;64(3):335-367. doi: 10.1007/s40262-024-01466-0. Epub 2025 Jan 11.
5
Comparison of efficacy and safety between loading-dose atorvastatin and rosuvastatin in cerebral infarction.
Am J Transl Res. 2024 Sep 15;16(9):4633-4642. doi: 10.62347/GQIE8716. eCollection 2024.
6
Self-nanoemulsifying drug delivery system for nebulization: fabrication and evaluation for systemic delivery of atorvastatin.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr;398(4):3829-3842. doi: 10.1007/s00210-024-03494-w. Epub 2024 Oct 3.
7
Statin treatment for primary and secondary prevention in elderly patients-a cross-sectional study in Stockholm, Sweden.
Eur J Clin Pharmacol. 2024 Oct;80(10):1571-1580. doi: 10.1007/s00228-024-03724-3. Epub 2024 Jul 16.
9
Unveiling the molecular mechanisms: dietary phytosterols as guardians against cardiovascular diseases.
Nat Prod Bioprospect. 2024 May 9;14(1):27. doi: 10.1007/s13659-024-00451-1.
10
Identification of novel genes associated with atherosclerosis in Bama miniature pig.
Animal Model Exp Med. 2024 Jun;7(3):377-387. doi: 10.1002/ame2.12412. Epub 2024 May 8.

本文引用的文献

3
Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association.
Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):e38-e81. doi: 10.1161/ATV.0000000000000073.
5
Primary Prevention With Statins in the Elderly.
J Am Coll Cardiol. 2018 Jan 2;71(1):85-94. doi: 10.1016/j.jacc.2017.10.080.
6
Use of Statins and Outcomes in Intracerebral Hemorrhage Patients.
Stroke. 2017 Aug;48(8):2098-2104. doi: 10.1161/STROKEAHA.117.017358. Epub 2017 Jun 29.
8
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
Eur Heart J. 2016 Oct 14;37(39):2999-3058. doi: 10.1093/eurheartj/ehw272. Epub 2016 Aug 27.
10
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
N Engl J Med. 2016 May 26;374(21):2021-31. doi: 10.1056/NEJMoa1600176. Epub 2016 Apr 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验